Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 14/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.45 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7811507 | 0.84 | CCR3 (0.47) | TPSAB1CCR3KDM4CCHRM2CACNA1B | |
| SCHEMBL9011020 | 0.84 | CCR5 (0.55) | TPSAB1CHRM2 | |
| SCHEMBL9011227 | 0.82 | ITGB3 (0.47) | CCR3 | |
| SCHEMBL9011044 | 0.79 | PKLR (0.47) | CCR3CHRM2 | |
| SCHEMBL9011012 | 0.76 | RAB9A (0.62) | — | |
| SCHEMBL31395273 | 0.76 | KMT2A (0.60) | CCR3CHRM2 | |
| SCHEMBL4396015 | 0.75 | TPSAB1 (0.61) | TPSAB1 | |
| SCHEMBL9011061 | 0.75 | CCR5 (0.54) | TPSAB1CHRM2 | |
| SCHEMBL9011116 | 0.74 | CCR5 (0.53) | TPSAB1 | |
| SCHEMBL15866801 | 0.74 | TPSAB1 (0.57) | TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5532371-A | SIDE EFFECT REDUCTION | SS PHARMACEUTICAL CO., LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
| US-5411972-A | Arylamide derivatives for treating hyperlipemia | SS PHARMACEUTICAL CO., LTD. (JP) | 1995-05-02 | — | — | US | disclosed |
| EP-0607536-A1 | Arylamide derivatives | SS PHARMACEUTICAL CO., LTD. (JP) | 1994-07-27 | — | — | EP | disclosed |